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NEPHROTOXICITY OF Cl'CLOSPORIN A IN 
LIVER AND KIDNEY TRANSPLANT PATIENTS 
G, B. G. KUNTM!.l..M S.IWATSUKI 
T. E. STARZL 
D.-p;mmmrs of Surg£T), Kuni~qsity of Colorado H.al!1l Sdmm 
Cu.ta and Dor.:n- s~ttqan~ Adminislralion Hospital, am~I 
Colorado 80262, U.SA. 
Summary In six of twelve orthotopic liver recipients 
nephrotoxicity was noted after 13-22 days 
of treatment with 16 -3±2·9 (SEM) mglkg per day of cycle-
sporin A (CyA). With a decrease in the daily CyA dose to 
9·2±2 -3 (SEM) mglkg kidney function returned to normal. 
No hepatic rejections occurred on this lowered CyA dose. In 
4 out of 66 kidney recipients a switch from a CyA dose of 
5,2-10,7 mglkg daily to azathioprine was done 4-8 months 
after transplant because of unsatisfactory kidney function, 
5uspectrd to be due to nephrotoxicity. In three patients, this 
resuhed in an improved graft function. A fourth transplant 
was lost to an irreversible rejection 13 days later. Thus CyA is 
nephrotoxic but this toxicity is easily reversed, even after 
many months of treatment, and the ease with which this 
complication can be managed suggests that nephrotoxicity .1 
should not diminish the high expectations that transplant 
surgeons have for CyA. 
Introduction 
C'iCLOSPORI!'-I A (CyA), a metabolite from the fungi 
Cylindrocarpon /ucidllm and TrichodiTma po/ysporum, was 
discovtred by Dreyfuss et aLI Its immunosuppressive 
properties were rust reported by Borel et a!. 2 The earliest 
clinical studies of CyA on kidney transplant patients were 
reported in 1978, when the possibility of nephrotoxic side 
effects was raised.3,4 CaIne et aJ. 3,S reported a putative acute 
. nephrotoxic syndrome leading to anuria or oliguria in II out 
of 32 patients treated with CyA. They thought that this 
problem waS ameliorated by inducing forced diuresis with 
fluids and mannitoL They r{'commended delaying ,the 
administration of the first dose of CyA until post-
transpbnta!ion diure~is was established. In our o\,'n 
experience, this early kidney failure was usually caused by 
acute rejection rather than by nephrotoxicity of CyA and 
could bt prevented or treated with ~teroidsKSIT Thus, we have 
started treatment with CyA preope.ratively. 
To clarify the question ofCyA nephrotoxicity further, we 
have studied renal function in liver transplant recipients who 
were treated with this drug. In addition, observations 
relevant to nephrotoxicity were made in four kidney graft 
recipients wbose therapy was changed from CyA to 
azathioprine 4-8 months after transplantation. 
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TABLE l-l'IErHROTOXICJn" FRO.\\ CYClosroRl:-; A FOt,"XD t:-: LIVER 
TRAI'SPlAST rAnE:-;TS 
Timcormax, 
toxicityartcr !.In" $trum 
,ransplanl creatinine CyA dose 
PalicDl (cb,,) (j.molll) (m&lk&) 
I 22 221 13·0 
4 22 548 17·5 
5 17 248 17·5 
6 13 424 17·5 
7 15 221 17·5 
9 (a) 13 8,13 20·0 
9 (b) 41 274 11,0 
McaruSE 17±3'8t 393±206 16·3±2·' 
"NephroloxicilY defincd .. a serum crealininc> 175,,",0111, 
tExc\uding 9 (b). 
Patients 
Non'lolic 
C)'Adosc 
(mc/ka) 
11-0 
8·2 
14·0 
7·2 
8·7 
7,5 
7,5 
'·2:1:2·3 
After livu'rransplantari"n, tweh'c patients were Heated ~ ... ith CyA 
and low doses of predni sone. Alit weh'e were gh'en one dose ofCy A, 
15-20 mglkg, kfore operation and this daily dose was continued 
afterwards intramuscularly or orally. Before operation and after· 
wards renal function was monitored \\;th daily serum creatinine 
(table I) and blood urea nitrogen (BUl\') determinations, plus one to 
t"'.o times weeklr creatinine clearances, Postopcrati\'ely, renal scans 
were done with Plf-h~puran and 99mTc.diethylmctriamine-penta-
acetic acid (DTPA), and in six patients the r~sults could be 
compared with similar preoperative studies, One potient died on the 
19th postoperative day from a complete hrpatic aner), thrombosis 
plus a partial ponal vein thrombosis. \,\'jth O:JC excep:ion, the rJeven 
suni\ing recipients now llave norlll3l liver function. The 
exceptional patient has chronic rejection with a bilirubin of 113 
lIDlollI, but he has not shown any s:gns of nephrOtoxicity with a CyA 
dose of9·5 mglkg. 
From December, 1979, to Serltmkr, 1980,66 patients giwn 67 
cada\'cric kidney rr.lnspl.l1llarions ha\'e reeeh'ed C"A and 
prednisone.6,7 In -1 of those 66 patients the immunosuppre;sion was 
changed after 4-8 months from CrA andpredni<o!le to azathio-
prine and prcd...,isone. The prednisone dose was kept constant . 
Indications and timing orthe switch arc listed in table II. 
Results 
Significant renal function abnormalities were noted on 
seven occasions in six of the twelve Iher lrall'p!.:2111 recipients_ 
The deteriorations occurred suddenly with shJrp rises in the 
serum creatinine and BUN after )3-22 days of CyA treat-
ment. A drop in urine output and weight gain was also noted. 
The CyA dose at the time ranged betwee.n II and 20 (mean 
16· 3) mglkg (tal?le I). The renal scans showed normal blood 
flow, with decreased clearance, a fmding described in kidney 
transplants as consistent with acute tubular necrosis (ATN).' 
After decreasing the CyA dose, the: foregoing changes in 
renal function promptly disappeared. The narrow margin 
between an acnptable situation and clinically oven 
T.\BLE 1I-I'EPHROTOXICITY 1:-; ob~Ai qoA~pmiA~qba PATIESTS FROM CYCLOSPORI:-; A R1:CORDED AS hfa~bv ruSCTlO:-: Jl'ST BEFORE 
afpCl:-D"qf~lDf~d CYClOSPORfN A 
P.litnt 
, 
12 
21 
Timt or changt to n.,hioprin. 
all., tr.".plan, (mo) 
8 
6 
4 
5 
pcrum<rt~tini~e on 
erA e;,mo\II)· 
274 
318 
407 
318 
~~------
---
C"A dose 
(;"g1l<g) 
JO.j 
7·0 
7·0 
5·2 
------
St:rum ere.umine on 3uthioprinc Indian ions ror chon,. of 
(;imolll)· immu nosupprcssion 
133 pus~ED!cd ncphroloxici:y plus 
.' htpato.icil)' (bilirubin 50 I'motlllt 
159 pusKIKI~Kd nephroto,;'i,)' 
230 Su,),,<,ocd nrphro:o.icit!, 
Kidnt), loss pllpp~~ f('d n<;!1:-o!oxi.:itY 
----------
-"Idnt} ryKin~tion fo; r:tre:us on .zJthiot'rjn( rtcorJt,d yyD~en lh: f~rKc:ior: hJd rt.·'h.-hcd oJ S!C3C)" stZatt'. Steroid Uc:atmcnt rcrruin(d l~nK:h:!nCtd during this ~riod 
('"t,bosor •• 10 - 20 mg'da)') 
*r.:i.nt 3 h.d. nn:m.1 her fur,Clion wi:hin 2 "'tdu, 
T .ff L .. ~crqIcbflorAovOUI19U1 
~tDfsrr trfotinine ~fyF 
40 
BUN (mmol/U 
~j"~·A!~~D_D ________ -",r-----'LJ 
Ta 10 2'0 3'0 40 Days 
Kidney function in liver recipient no. I. 
Cy'" dOlot of 20 m~DkI daily rrsuh,d in a ,evere episode Orutaemia. Patient 
not dialy~dK MttT reduction in CyA dose, kidney function returned 10 normal. 
bta inK:rca~ ill CyA from 7· 5 to 11·0 mglkg d.i1y ClUed second 
c!<I<rioralion in k.idncy function; function again nonnal after CyA dose 
fKK:!j~stmcntK 
nephrotoxicity is exemplified by liver patient 9. Early' 
prClnClunced nephrotoxicity was relieved by reducing CyA 
from 20·0 to 7·5 mglkg per day. Later) an increase in the 
CyA from 7·5 to 11· 0 mglkg resulted in a second example of 
nephrotoxicity (see figure). A third episode was obsen'ed one 
mO:1th after the time shown in the figure when the dose of 11 
mglkg was temporarily reinstituted. The non-toxic CyA dose 
ha~ been found to range from 7· 4 to 14· 0 (mean 9· 2) mglkg 
in patients with liver grafts. None of these patients have 
shown any signs of acute hepatic rejection. 
51 CO:-;\,ERSIOS 
Creatinine: Il'moVl:O'Oll mgfdl 
Bilirubin: Il'moVl:O'059 mg/dl 
Urea nitro~cn: I mmofK~: I . 4 mg/dl 
JUst before changing from CyA to azathioprine) a114 of the 
rena/transplant patients h~d good renal blood flow on scans 
which were interpreted as consistent_with ATN. After the 
5\\ itch, renal function improved within 1-3 w::eks in three 
recipients with halving of the average serum creatinine con-
centrations. Two of these three recipients had a nor mal renal 
funnion after the transplant. It took 5-7 months on a stable 
CyA dose of7 to 10· 7 mglkg for the nephrotoxicity to reveal 
itself. The founh patient txperienced graft rejection within 
13 days of changing to azathioprine. 
Discussion 
The opportunity to measure renal function in twelve liver 
transplant recipients permits conclusions to be drawn about 
the nephrotoxicity of CyA without the confusion inherent 
with such studies on kidney transplant patients. The good 
liH:r function which was achieved in eleven of these patients 
precludes the: hepatorenal syndrome as a factor. Six patients 
e.\hibited nephrotoxici\y in doses of II '0-20' 0 mg/kg daily. 
The complication responded to dose reduction and was com-
pletely reversible. 
The evidt:nce of nepJilfotoxicity is almost as convincing in 
(he four renal recipients who were changed from CyA to 
azathioprine. Here) nephrotoxicity apparently occurrc:d in 
do,es 2S low as 5·2 mglkg daily. The risk of such a therapeutic 
cha:1ge under these circum~tances W3S shown by the prompt 
r~it:ction of one of the four kidneys despite substitution of 
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azathioprine for CyA. In the exceptional case, just as in the 
other three, the renal scans before the drug switch had shown 
the combination of good perfusion plus impaired clearance) 
which we have associated with nephrotoxicity rather than 
rejection. ' 
Although nephrotoxicity was thus a feature ofCyA therapy 
after both liver and kidney transplantation, the usefulness of 
the drug was little affected. Dose adjustments were easy to 
make and were not followed by rejection in most instances. In 
our view, CyA remains a major advance in clinical immuno-
suppression. 
Requtsts for reprints should be Kddr<~d to T. E. S., Uninrsity of 
Pittsburgh, Departm<nt of Sur,,,),, 10S4 Scaife Hall, PitlSbur,h, 
P<nnsyh'ania, 15261, U.S.A. 
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Preliminary Communication 
INHIBITION OF PENT AGASTRIN-STIM ULATED 
AND OVERNIGHT GASTRIC SECRETION BY 
LM24056, A NEW PHENOTHIAZINE·DERIVED 
ANTISECRETORY DRUG 
E. J. S. BOYD' K. G_ WORMSLEY 
Deparlment of Thcrapelllics, Uni-..oasity oj Dundee 
Summary LM24056, a tricyclic drug) weakly inhibited 
pentagastrin·s! imulated gastric secretion 
but was a powerful inhibitor of nocturnal gastric secretion in 
5 healthy volunteers. In 23 patients with duodenal ulcer, 
LM24056 at doses of 100) 200, and 300 mg inhibited ov!!/'-
night acid output by 310/0) 700/0, and 81%) and overnight pep" 
sin secretion by 15%,50%, and 690/0, respectively. Inview of 
its gastric inhibitory effects, LM24056 warrants clinical 
evaluat~on in the treatment of peptic ulcer disease. 
INTRODUCTION 
LM24056 is a phenothiazine (fig. l)(Pharmuka, Gennevil-
liers, France) which has been shown in animal studies to 
inhibit the gastric secretory response to pentagastrin) 
2·deoxyglucosc) carbachol, and food) but not the response to 
histamine. The drug protects rats ag3inst experimental gas· 
tric ulceration induced by indomethacin and phenylbuta· 
zone. We have studied the errects ofLM24056 on pentagas-
trin·stimuh.:ed and overnight gastric secretion in man in 
order to determine wherher the drug has ther3peutic poten· 
tial for the tre~;mt:nt of peptic ulcer.ation. 
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METHODS' 
Five ht21tby yDoluK11e~;; I;Kn~trwent rv.o t~ts in r2naom order on 
scr~;Kie day ... In c"ci; ld:, ~ftcr 3n o;.crnighr- f251, tbe dUOOC:lUIn 
W25 intub:llcd ,,,d 2 HI:. '«3 n2,og;;stric rulx was positioned for 
O~p:;KtiorK of p: tric C(·::lcD:S. '32,21 psaic ,h:r ctions we're coll~ted 
in 15 rr;in ~O;r;rks for I b, ;;nl, which pcntcg2strin was adm.inis-
le:ed by c0mt.nt i::lc<" ent·"S inf''''e.n al a dose of2 I'g kg-I b-I_ 
mt;:;:<RMR;r;n·I:ir!1·":~dcd Fs::ic ju:ee was colltClt1:l in 15 min 
sK<-::;:l~s for C:;O min. nK·Mg~~~ut I.I ,e h~t 155 r.,rrolll ~od:um 
EhkK:id~ yD::~ ic..'·c,,·d dco .. n 1~K~ cuo-:!c: .1 L'_,c dl 3 r.,lfrr.in. At the 
~:<g1 of the eod CEF::~;o" c>i,r[ ri~~CfRS OC~mg {2S CD1g~hed 
t .. ~:D-:~F;n JC,-,l EIrrrK:D-:R~ly·i=:lK-~l !-~~i;-Kc ~~D~DDD;~:lln~ or ]0 irJ or~::~ii1e 
~: .. ,iuiivr. "D~Eg!1; y:KKD4:~ !:;~:::;~::II"j c;.;<r.,6 2 ::-"':n ·'!0',\,·n f~g~ dKKKiE~c:-K~l tube. 
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Thnoh.:rr:e of h2mi, juice ;I~p;rPtea curing edeh 15 min period \Io2S 
re-cordtd ana a ~=I;Ilc w.s Os~;;i~d for rH, acid conc~nt::eionI ;;nd 
peptic ;;(1i\1ty, 
23 p;;titDts (18 wi.h .Cli\e duodenal ulcers and 5 volunteers who 
were knOV.7110 han l>';gh acid outputs) h.d gastric juice collt"Ctions 
on two sc;:;;r;;te n:ghts. They haa a light tea at 6 P.M. 2nd g:lStric 
juice wascolleGN from9 P.M_ ti1l9 K~_M_ Ll-,e no::.xt morning. On onc of 
the nights iyyO~{lRS was ta].;en maUy 2t 7 P.M. 6 subjects rl'Ccived 
L\124056 100 mg, 11 rt(civcd 200 mg, 4!Jd 6 received 300 mg. Gas-
tri.: juice W.$ col: .. cttd in hourly samples, the volume W2S rn:orded 
~nd a s:;;nple <s~<yK-d for pH, acid concenlf;;tion, and peptic 
2cti,ity. pH "'21 rK1~"pr;K-d by mt2ns of an .uto:.:.atic tiu2tor 
EoKtiEI;rKctc~FK Acid cO;;ct:1t:ation was cettf::1incd by titration to pH 
7·0 wi;b·~cK>diu!ll hy6oxide. Pepsin was :u.!-ayed by tbe mtthod of 
Bers12d. I · . 
RESULTS 
Re.tponst 10 P."7ltaga.Jlri71 . 
1.1.124056 (200 mg) adminislered inmduodcnally 
inhibited mean 2cid output during the 90 min OfpcDl3g2Strin 
.stimulation by 29o/c cnd pepsin output by 220/0 (fig. 2). Reduc-
tion in acid OUtP'J! W2$ 2ttribu!ablc 10 a rf'duction in the nile 
(volume) ofstcrction, which fell by a me~n 0[3';%, The COD-
n:ntr2uons of acid And pepsin did not ch;..ngc 5igniIicantly, 
O .. ,-;-r.ighr G:mn·c Slc71:io71 
All doses ofL\12.;056 reduced o· .. crnigbl ~cid ~fld pepin 
ou:;U! i:J a do~e-<ltpn~dcnt ~<!nfltr (fig. 3). \'.,'j.h lOll cg the 
dE:crE;O~e w~s ;I;trjh;:<Do~~ to a r,ou(1ion ~ole1y in the :ate of 
~Icre:ionK HO·,:.tVCT, ',;·ilh 200 rr.g "rod 300 mg E~"e :acmm-
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